Background {#Sec1}
==========

Patients with cardiac arrest not responding to standard cardiopulmonary resuscitation (CPR) can be resuscitated by veno-arterial extracorporeal membrane oxygenation (ECMO-CPR). Advances in technology and equipment have made ECMO-CPR much more attractive during recent years, and its use is increasing. The enthusiastic quest for novel resuscitation techniques may be due to the fact that standard CPR frequently fails. Although ECMO-CPR is claimed to represent "a frontier of resuscitation" \[[@CR1]\], it is not an established treatment modality. No controlled clinical ECMO-CPR studies exist, but observational studies have been published \[[@CR2]--[@CR7]\]. Many centres have reported positively on their clinical experiences as reviewed recently by Fagnoul et al. \[[@CR8]\]. Studies on ECMO-CPR usually focus on survival until hospital discharge and on post-arrest neurological sequelae. End-points in experimental studies are frequently the regain of spontaneous circulation (ROSC) and post-arrest brain tissue damage. A clinical problem after ROSC, however, is the early post-arrest cardiac dysfunction with circulatory failure-increasing the risk of adverse neurological function and poor outcome in resuscitated patients \[[@CR9]\]. Detailed knowledge of cardiac function post-arrest is therefore needed. Few data exist on cardiac dysfunction after ECMO-CPR. The purpose of the present study was twofold; (1) to investigate ECMO-CPR in an experimental pig model and (2) to assess the early post-arrest left ventricular (LV) function by cardiac magnetic resonance imaging (MRI). We hypothesised that a significant early post-arrest LV dysfunction could be demonstrated with this model using MRI. Cardiac MRI allows accurate measurements of motions, volumes and flow in the beating heart and is not previously used to describe early post-arrest cardiac dysfunction.

Methods {#Sec2}
=======

Overall design and details {#Sec3}
--------------------------

The study was a controlled experimental animal study. A listing of experiment details is presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Animals and anaesthesiaPig (sus scrofa domestica)    StrainCrossbreeding    Numbers included8    Gender3 female 5 male    Weight49.7 ± 2.3 kgVentilation    ModeVolume control    Tidal volume10 ml/kg    PEEP5 cm H~2~O    Respiratory rate18/min    I:E ratio1:2    FiO~2~40 %Premedication (i.m)    Azaperone4 ml 40mg/ml (3 mg/kg)    Ketamine30 ml 50mg/ml (30 mg/kg)    Atropine1 ml 1mg/ml (20 μg/kg)Anaesthesia (i.v)    Pentobarbital4 mg/kg/h    Morphine2 mg/kg/h    Midazolam0.15 mg/kg/h    Rocuronium3 mg/kg/hEuthansia (i.v)    Pentobarbital20 ml 50 mg/ml (20 mg/kg)    Morphine5 ml 10 mg/ml (1 mg/kg)    Potassium chloride50 ml 1 mmol/ml (1 mmol/kg)Animals and anaesthesia used in the experimentsWeight as mean ± standard deviation; *PEEP* positive end-expiratory pressure, *I:E ratio* the ratio of inspiratory time (I) to expiratory time (E), *FiO* ~*2*~ fraction of inspired oxygen, *i.m*. intra muscular, *i.v*. intra venousTable 2EquipmentAccessoriesNameCompanyLocation    VentilatorLeon PlusHeinen & LöwensteinBad EmsGermany    Ventilator in MRIFabius MRIDrägerwerk AG & CoLübeckGermany    Left ventricle pressure transducerMPR-500Millar InstrumentsHouston, TXUSA    Venous vascular introducerAVA High-Flow M3L9FHS 9FrEdwards LifesciencesIrvine, CAUSA    Pulmonary artery catheterSwan-Ganz CCOEdwards LifesciencesIrvine, CAUSA    Arterial vascular introducerRadifocusintroducer II 8FrTerumo EuropeLeuvenBelgium    Per venous pacing leadQstim 5FrVascoMed GmbHBinzenGermany    Pulmonary artery monitorVigilance II MonitorEdwards LifesciencesIrvine, CAUSA    Pressure transducer softwareMikrosound Presenter 18.11.2011Vestfold university collegeTønsbergNorway    DefibrillatorCodeMaster XL+Hewlett PachardLexington, KYUSA    Data analysis softwareGraphpad prism 6.04GraphPad SoftwareLa Jolla, CAUSA    Statistical softwareSPSS v.22SPSSChicago, ILUSAMRINameCompanyLocation    MRI Scanner w/softwarePhilips Achieva 3 TeslaPhilips Medical SystemsDA BestNetherland    MRI tagging analysis softwareDiagnosoft HARP 3.0DiagnosoftDurham, NCUSA    MRI cine/phase-contrast image analysisSegment version 1.9 R2585Medviso ABLundSwedenECMO circuitNameCompanyLocation    CannulaeArterial: DLP Femoral 14Fr Venous: DLP Jugular 21FrMedtronic IncMinneapolis, MNUSA    Centrifugal pumpBiopump + BPX-80Medtronic IncMinneapolis, MNUSA    OxygenatorAffinity NTMedtronic IncMinneapolis, MNUSA    ConsoleBiomedicus 550 Bio-consoleMedtronic IncMinneapolis, MNUSA    Flow transducerBioProbe TX50Medtronic IncMinneapolis, MNUSA    Temperature probeModel TP Series 400 Thermistor ProbeMedtronic IncMinneapolis, MNUSA    Heat-exchangerStöckert Heater-Cooler System 3TSorin GroupMilanoItaly    Oxygen/air mixerSechrist Model 20090Sechrist IndustriesAnaheim, CAUSAEquipment used in the experiments

Animal welfare {#Sec4}
--------------

The experimental protocol was approved by the Norwegian National Animal Research Authority. The animal experiments were performed in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (European Council, ETS No. 170). Personnel who handled the animals were certified with Federation of Laboratory Animal Science Associations category C. Detailed information according to the ARRIVE guidelines (Animals in Research: Reporting In Vivo Experiments) \[[@CR10]\] is presented in Additional file [1](#MOESM1){ref-type="media"}: Table S1. A pig model was chosen because of the close similarities to human cardiac anatomy and physiology, also adequate for the use of standard equipment and clinical MRI sequences.

Animals and anaesthesia {#Sec5}
-----------------------

Eight pigs were included in the study; each pig was kept fasting overnight-with free access to water, pre-medicated in the pig box housing and weighted before a short transport to the MRI research operating theatre. A mixture of intravenous anaesthesia standardised by weight and suspended in Ringer's acetate solution was infused at 10 ml/kg/h (Table [1](#Tab1){ref-type="table"}). The anaesthesia left no reaction to intermittent sharp hoof pinching or surgery and was chosen also to provide haemodynamic stability and the safe use of neuromuscular blockade \[[@CR11], [@CR12]\].

Preparation {#Sec6}
-----------

Each pig received a tracheostomy and intravascular catheters by a midline neck incision. A micro-manometer pressure transducer was positioned in the LV via an 8 French vascular introducer in the right carotid artery (Table [2](#Tab2){ref-type="table"}). Both internal jugular veins were cannulated with 9 French vascular introducers and used to place a pulmonary artery (PA) catheter and a temporary pacing lead to the right ventricle. The femoral artery and the right external jugular vein were cannulated with 14 French and 21 French ECMO cannulae, respectively, using a guiding obturator placed over a guide-wire during fluoroscopy. To prevent ECMO clotting, a bolus of intravenous heparin 2 mg/kg followed by infusion 0.5 mg/kg/h was given to obtain an activated clotting time ≥300 s. Mechanical ventilation was set to keep PaO~2~ within 20 ± 5 kPa and PaCO~2~ within 5.0 ± 0.5 kPa. Each pig had standard monitoring during the experiment-including electrocardiography (ECG), pulse oximetry, end-tidal expiratory CO~2~, hourly urine output and oesophageal temperature.

Experimental protocol {#Sec7}
---------------------

### Baseline assessments {#Sec8}

After preparation and a following 30-min stabilisation period, baseline cardiac MRI and haemodynamic measurements of LV function were obtained. An arterial and a mixed venous blood sample were also analysed.

### Establishment of ECMO {#Sec9}

After baseline assessments, the pig was connected to a custom-made femoro-jugular veno-arterial ECMO circuit (Table [2](#Tab2){ref-type="table"}). The ECMO consisted of an 86 ml centrifugal blood pump and a 270 ml micro-porous polypropylene hollow fibre oxygenator with a 2.5 m^2^ surface area. An oxygen/air mixer enabled an adjusted sweep gas oxygen fraction and sweep gas flow rate. The circuit was without surface coating and primed with Ringer's acetate solution. The machinery was initially set to standby with the vascular lines clamped.

### Cardiac arrest and resuscitation {#Sec10}

Ventricular fibrillation (VF) was induced by an electrical stimulator connected to the right ventricular pacing lead. VF was confirmed by ECG shape and aortic blood pressure drop, and the ventilator was set to standby. After 15 min of untreated VF, ECMO-CPR was initiated with initial blood pump speed at the maximum 4540 rounds per minute. The sweep gas was set at the same flow rate as the ECMO blood flow rate, the fraction of oxygen to 100 % and the circuit temperature to 38.0 °C (normothermia in the pig). After 5 min of ECMO-CPR, fibrillation was terminated by external damped sinusoidal waveform 360 Joule monofasic shocks through standard anterior/anterior pads until sinus rhythm was obtained. The extracorporeal support continued at the same blood flow rate for a total of 150 min. Repeated blood gas analyses were performed, and the sweep gas flow rate and the oxygen/air mixture were adjusted according to the protocol. The lowest acceptable mean aortic pressure (MAP) and pulse pressure after defibrillation and regain of spontaneous cardiac beating (ROSB) was set by protocol consensus to 50 and 15 mmHg, respectively. Intravenous adrenaline (epinephrine) 10--25 μg boluses were given to ensure these criteria were met initially. If in need of continued inotropic support, infusion of the beta-adrenergic agonist dobutamine 5 μg/kg/min was started \[[@CR13]\], and the infusion rate was adjusted if necessary. Each pig was weaned from ECMO during a 60 min period with successive 0.7 l/min reductions in blood flow rate every 10 min, to zero support. A 60-min stabilisation period followed before post-arrest assessments.

### Post-arrest assessments {#Sec11}

At 285 min post-arrest, cardiac function was re-assessed by the PA catheter and the LV pressure transducer. Arterial and mixed venous blood samples were analysed, and a second cardiac MRI was made. Finally, the pig was euthanized.

Cardiac MRI measurements {#Sec12}
------------------------

Image acquisition, interpretation and post-processing were done according to the recommendations from the Society for Cardiovascular Magnetic Resonance \[[@CR14]\]. Cardiac MRI images were analysed by the software Segment version 1.9 R2585 (http://segment.heiberg.se) \[[@CR15]\] and by Diagnosoft HARP 3.0.

The LV was assessed by adjacent parallel short-axis slices covering the full volume of the LV and by long axis slices. Series of cinematographic images of the cardiac cycle were recorded by retrospective ECG-gating without breath-holds. The images were analysed to estimate end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV = EDV-ESV), ejection fraction (EF = SV/EDV) and cardiac output (CO = SV · heart rate (HR)). In addition, mid LV radial wall thickening and mitral annular plane systolic excursion (MAPSE) were measured. Wall thickening was averaged from measurements in the septum and the lateral wall, and MAPSE averaged from antero-septal-and postero-lateral measurements.

Slices in short axis were also magnetically gridded throughout the cardiac cycle (tagging) to assess peak global systolic LV circumferential (Lagrangian) strain by harmonic phase analysis \[[@CR16]\]. Strain assessment provides information on the process of myocardial deformation; it can be extended to include fine details \[[@CR17]\], and it also known to quantify myocardial function during echocardiography \[[@CR18], [@CR19]\].

Phase-contrast imaging with blood velocity encoded through-plane images of the mid-ascending aorta was also included to assess LV stroke volume (SV~phase~) and cardiac output (CO~phase~). It has been stated that this technique "should provide the most accurate measurement available of cardiac output" \[[@CR20]\].

For further descriptions of cardiac MRI measurements the reader is kindly referred to Additional files [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"} with the accompanying illustrations in Additional file [4](#MOESM4){ref-type="media"}, [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"}, [7](#MOESM7){ref-type="media"} and [8](#MOESM8){ref-type="media"}.

Haemodynamic measurements {#Sec13}
-------------------------

The PA thermodilution CO measurements (CO~PA~) were performed with injections of 10-ml ice-cold isotonic glucose, and the CO~PA~ was calculated as the average value of three consecutive measurements. Central venous pressure (CVP) was measured, and the SV (SV~PA~ = CO~PA~/HR) and the systemic vascular resistance (SVR~PA~ = (MAP-CVP)/CO~PA~∙80) were calculated.

The LV pressure transducer measurements were recorded on a separate PC monitoring system and analysed offline with custom-built software based on a visual programming language (Table [2](#Tab2){ref-type="table"}) \[[@CR21]\]. The maximum systolic LV pressure (LVP~max~) and the maximum positive and negative first time derivate of LV pressure (dP/dt~max~ and dP/dt~min~) were measured, in addition to the end-diastolic LV pressure (EDP) and the end-systolic LV pressure (ESP). Systolic duration was measured from ECG R-peak to dP/dt~min~ and diastolic duration from dP/dt~min~ to onset of systole. Isovolumetric contraction time (IVC) was measured from ECG R-peak to dP/dt~max~. The isovolumetric relaxation constant tau was calculated using Weiss method \[[@CR22]\] in a 50-millisec time-frame starting at dP/dt~min~. LV afterload was estimated from arterial elastance (Ea = ESP/SV).

Measurements of oxygen consumption and oxygen delivery {#Sec14}
------------------------------------------------------

The arterial and venous oxygen content (C~a~O~2~ and C~v~O~2~) were calculated from the arterial and mixed venous blood samples, respectively. Oxygen delivery (D~O2~ = CO∙CaO~2~) and oxygen consumption (V~O2~ = CO∙arterio-venous oxygen difference (C~a~O~2~ -C~v~O~2~)) were calculated.

Outside the MRI scanner continuous measurements of HR, MAP and mean pulmonary artery pressure (MPAP) were recorded throughout the experiments (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Continuous haemodynamic measurements (outside the MRI scanner). Continuous HR (heart rate), MAP (mean aortic pressure) and MPAP (mean pulmonary artery pressure) during the experiment, outside MRI scanner, shown as mean values (*black line*) ± standard deviation (*grey*). Cardiac arrest (VF) was induced at time 0 (*bottom timeline*, *black triangle* at *dotted line*). ECMO-CPR was started at time 15 (*separate dotted line*) and defibrillation was done at time 20 (*open triangle*). ECMO continued for 150 min before a 60-min stepwise weaning. Cardiac MRI of the beating heart was made \~60 min pre-arrest, and \~300 min post-arrest. The pig was euthanized after the post-arrest cardiac MRI (*bullet point*)

### Statistical analysis {#FPar1}

Statistical analyses of normality (D'Agostino-Pearson omnibus and Shapiro-Wilk) and of equality of variances (Levenes) supported the use of parametric tests. Data are reported as mean ± standard deviation if not otherwise stated. The statistical significance level *α* was set to 0.05. A paired two-tailed *t* test was used to compare baseline- and post-arrest measurements. The degree to which volumetrically and phase-contrast estimates of SV change correlated was quantified by a Pearson's correlation analysis.

Results {#Sec15}
=======

The pigs weighed 49.7 ± 2.3 kg, preparation took 119 ± 29 min and cardiac MRI scan time was 63 ± 15 min. Prior to induction of cardiac arrest activated clotting time was 349 ± 83 s, and ECMO circuit priming volume was 538 ± 17 ml. The experiments lasted 747 ± 71 min.

Success of defibrillation {#Sec16}
-------------------------

All animals were successfully defibrillated by a median of 1 shock (range 1--4). MAP at the time of defibrillation was 52 ± 8 mmHg with an ECMO blood flow rate of 4.60 ± 0.15 l/min. VF spontaneously reemerged after ROSB in two pigs demanding one additional defibrillation in both.

Continuous haemodynamic measurements {#Sec17}
------------------------------------

Continuous HR, MAP and MPAP outside the MRI scanner are presented in Fig. [1](#Fig1){ref-type="fig"}. A considerable leap in HR was observed immediately following the defibrillation. The HR slowed gradually during the period of ECMO-CPR, but severe tachycardia with an approximate frequency of 150 beats/min remained throughout the experiment. MAP increased to a maximum of 77 ± 15 mmHg 2 min after defibrillation. MAP then dropped over the next 13 min to a low point of 49 ± 9 mmHg 20 min after initiation of ECMO-CPR. A further decrease in MAP was prevented by intravenous boluses of adrenaline and infusion of dobutamine. The median total dose of dobutamine and adrenaline was 10.3 mg (range 0--19.5 mg) and 80 μg (range 0--340 μg), respectively. MPAP changed in parallel with MAP to a maximum of 20 ± 5 mmHg 2 min after defibrillation. Both pressures stabilised as adrenaline and dobutamine were added. During the period of stepwise reductions in ECMO blood flow rate, MPAP increased in steps, reaching 22 ± 4 mmHg when weaning was completed. All animals could be successfully weaned from ECMO as dictated by the protocol. During the 60-min stabilisation period following ECMO separation, the haemodynamics remained unchanged (Fig. [1](#Fig1){ref-type="fig"}).

Baseline and post-arrest haemodynamic measurements and blood gas values {#Sec18}
-----------------------------------------------------------------------

Haemodynamic measurements and blood gas values at baseline and post-arrest are presented in Table [3](#Tab3){ref-type="table"}. The substantial increase in HR post-arrest limited the reductions in CO. Systolic duration and isovolumetric contraction time were shortened by 33 ± 8 % and 17 ± 12 %, respectively, whereas diastolic duration decreased by 57 ± 17 %. LV afterload estimated by Ea increased post-arrest, and there was also a noticeable rise in MPAP. There was a minor increase in dP/dt~max~ whereas LVP~max~ did not significantly change; neither did EDP, dP/dt~min~ nor tau.Table 3Haemodynamic measurements and blood gas valuesA. Pulmonary artery catheter measurements and MAP    VariableBaselinePost-arrestMD (95 % CI)*p* value    HR~PA~ beats/min86 ± 22147 ± 2861 ( 37 86)*p* \< 0.001    MAP mmHg84.3 ± 13.174.6 ± 16.8−9.6 (−27.0 7.8)*p* = 0.23    CO~PA~ l/min4.5 ± 0.63.8 ± 0.4−0.72 (−1.5--0.08)*p* = 0.07    SV~PA~ ml53 ± 626 ± 3−27 (−33--22)*p* \< 0.001    MPAP mmHg17.8 ± 3.623.6 ± 4.35.9 ( 3.4 8.4)*p* \< 0.001    CVP mmHg6.3 ± 2.66.3 ± 3.20.0 (−2.0 2.0)*p* = 1.0    Wedge mmHg8.7 ± 3.78.5 ± 3.4−0.2 (−3.4 3.1)*p* = 0.89    SVR dyne•s/cm^−5^1390 ± 2321438 ± 28848 (−114 209)*p* = 0.51B. Left ventricle pressure transducer measurements    VariableBaselinePost-arrestMD (95 % CI)*p* value    LVP~max~ mmHg99.2 ± 7.191.4 ± 14.4−7.9 (−23.4 7.6)*p* = 0.27    EDP mmHg15.5 ± 4.014.7 ± 2.5−0.8 (−5.4 3.9)*p* = 0.71    dP/dt ~max~ mmHg/sec1440 ± 209.52034 ± 549.4594.1 (15.3 1173)*p* = 0.046    dP/dt~min~ mmHg/sec−2086 ± 285−1715 ± 419371 ( −185 926)*p* = 0.16    tau msec32.8 ± 3.033.5 ± 7.30.68 (−5.7 7.1)*p* = 0.68    Ea mmHg/ml1.04 ± 0.211.67 ± 0.470.63 (0.21 1.06)*p* = 0.009    DD msec440 ± 89190 ± 40−250 (−336--165)*p* \< 0.001    SD msec328 ± 19220 ± 19−109 ( −133--84)*p* \< 0.001    IVC msec50 ± 742 ± 6−9 (−14--3)*p* = 0.007C. Blood gas analyses    VariableBaselinePost-arrestMD (95 % CI)*p* value    Haemoglobin g/dl8.4 ± 0.78.2 ± 0.8−0.24 (−0.49 0.02)*p* = 0.06    PaO~2~ kPa22.6 ± 2.120.1 ± 3.5−2.5 (−4.7--0.34)*p* = 0.03    PaCO~2~ kPa5.2 ± 0.45.3 ± 0.30.14 (−0.29 0.57)*p* = 0.46    pH7.50 ± 0.037.47 ± 0.04−0.03 (−0.07 0.01)*p* = 0.08    Base excess mmol/l6.63 ± 1.254.73 ± 1.79−1.9 (−3.02--0.78)*p* = 0.005    Lactate mmol/l0.88 ± 0.211.34 ± 0.540.46 (−0.03 0.95)*p* = 0.06    Ca^2+^ mmol/l1.29 ± 0.071.26 ± 0.07−0.025 (−0.08 0.03)*p* = 0.32    SvO~2~ %69.4 ± 13.144.0 ± 7.9−25.4 (−36.4--14.4)*p* \< 0.001    DO~2~ ml/min572 ± 124499 ± 119−74 (−228 79)*p* = 0.29    VO~2~ ml/min164 ± 49273 ± 46109 (57 160)*p* = 0.002*HR* ~*PA*~ *, CO* ~*PA*~ *and SV* ~*PA*~ pulmonary artery catheter assessments of heart rate, cardiac output and stroke volume, *MAP* mean aortic pressure, *CVP* central venous pressure, *Wedge* pulmonary arterial wedge pressure, *SVR* systemic vascular resistance, *LVP* ~*max*~ systolic left ventricular pressure maximum, *EDP* end-diastolic pressure, *dP/dt* ~*max*~ *and dP/dt* ~*min*~ maximum and minimum LVP time derivates, *tau* isovolumetric relaxation constant, *Ea* arterial elastance, *DD* diastolic duration, *SD* systolic duration, *IVC* isovolumetric contraction time, *S* ~*V*~ *O* ~*2*~ mixed venous oxygen saturation, *D* ~*O2*~ oxygen delivery, *V* ~*O2*~ oxygen consumptionValues are expressed as mean ± standard deviation. *MD* mean difference, *CI* confidence interval, significance level *p* ≤ 0.05

Arterial blood gas values remained virtually unaltered post-arrest, and the haemoglobin concentration was stable (Table [3](#Tab3){ref-type="table"}). The D~O2~ was maintained due to the increased HR, but mixed venous oxygen saturation dropped from 69.4 ± 13.1 % to 44.0 ± 7.9 % (*p* \< 0.001) post-arrest, corresponding to a 66 ± 38 % increase in V~O2~ at almost unchanged D~O2~ (mean difference --74 ml/min (*p* = 0.29)).

Baseline and post-arrest cardiac MRI {#Sec19}
------------------------------------

Cardiac MRI measurements at baseline and at 308 min ± 8 min post-arrest are presented in Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. LV function was severely reduced post-arrest, as EF decreased from 61 ± 5 % to 34 ± 8 % (*p* \< 0.001) and SV decreased from 62 ± 9 ml to 30 ± 7 ml (*p* \< 0.001). The lowered EF was related to a 58 ± 39 % increase in ESV as EDV was maintained (mean difference −8.9 ml (*p* = 0.22)). The reduction in SV was consistent with the change in SV~phase~ (Pearson *r* = 0.7). The minor reduction in CO (0.5--0.7 l/min) was not statistically significant. Consistent with the reduced SV the absolute value of global systolic circumferential strain decreased from −17.4 ± 4.2 % to −5.1 ± 3.3 % (*p* \< 0.001) and MAPSE was reduced from 12 ± 1 mm to 6 ± 1 mm (*p* \<0.001). Similarly, mid LV radial wall thickening was severely affected by a reduction from 58 ± 18 % to 20 ± 9 % (*p* \< 0.001). The reductions in MAPSE and wall thickening were consistent between the different measuring locations in the LV.Table 4Cardiac MRI measurementsVariableBaselinePost-arrestMD (95 % CI)*p* valueHR~MRI~ beats/min83 ± 19153 ± 3270 (36 103)*p* = 0.002CO~phase~ l/min4.5 ± 0.63.8 ± 0.9−0.7 (−1.7 0.3)*p* = 0.12SV~phase~ ml56 ± 926 ± 9−29 (−41--18)*p* \< 0.001EDV ml100 ± 1092 ± 15−8.9 (−25 7)*p* = 0.22ESV ml39 ± 561 ± 1523 (10 35)*p* = 0.003Wall thickening septum %56 ± 1817 ± 11−39 (−53--25)*p* \< 0.001Wall thickening lat %59 ± 3122 ± 10−37 (−65--9)*p* = 0.016MAPSEantsept mm10 ± 24 ± 1−6 (−7 -4)*p* \< 0.001MAPSEpostlat mm15 ± 18 ± 2−7 (−9 -5)*p* \< 0.001*HR* ~*MRI*~ heart rate during MRI, *CO* ~*phase*~ *and SV* ~*phase*~ cardiac output and stroke volume by cardiac MRI phase-contrast technique, *EDV* end-diastolic volume, *ESV* end-systolic volume, *Wall thickening* ~*septum*~ *and Wall thickening* ~*lat*~ mid left ventricular radial wall thickening in septum and lateral wall, *MAPSE* ~*antsept*~ *and MAPSE* ~*postlat*~ mitral annular plane systolic excursion measured anteroseptally and posterolaterallyValues are expressed as mean ± standard deviation. *MD* mean difference, *CI* confidence interval; significance level *p* ≤ 0.05Fig. 2Baseline and post-arrest cardiac MRI. EF (ejection fraction), SV (stroke volume), CO (cardiac output), MAPSE (mitral annular plane systolic excursion), strain (peak global systolic left ventricular circumferential strain) and wall thickening before (*baseline*) and at \~300 min post-arrest. A paired two-tailed *t* test was used to compare baseline- and post-arrest measurements; asterisk: *p* value \< 0.001

Discussion {#Sec20}
==========

In this study, ECMO-CPR emerged as an effective tool resuscitating the heart from long-lasting cardiac arrest. Fifteen minutes of VF induced a severe early post-arrest LV dysfunction that was demonstrated in detail by cardiac MRI. This is the first study to describe early post-arrest LV dysfunction by cardiac MRI.

There are no ECMO-CPR guidelines for patients with refractory cardiac arrest. As a consequence, several strategies are implemented targeting various circuit flows, arterial pressures, oxygen saturations and core temperatures. Indications may also differ between centres, although a refractory normothermic arrest with a no-flow period of less than 5 min will generally be accepted for ECMO-CPR. A 60-min time-frame is often stated as the clinical accepted limit of low-flow (the period of standard CPR) before ECMO is established. In animals, without extracorporeal support the probability of successful ROSC decreases drastically when VF is untreated for more than 10--12 min, and it is almost impossible to achieve sustainable ROSC in pigs after 15 min of untreated VF \[[@CR23]--[@CR26]\]. In the present study, the 15 min duration of cardiac arrest followed by ECMO-CPR was chosen to allow early survival \[[@CR23], [@CR27]--[@CR30]\], but with a significant post-arrest cardiac dysfunction that could be examined by cardiac MRI in a stable state.

ECMO-CPR strategy {#Sec21}
-----------------

All pigs were successfully resuscitated by our protocol using a short (150 min) ECMO-CPR run with maximal flow, initially 100 % oxygen, normothermia, MAP above 50 mmHg and pulse pressure above 15 mmHg. The diameter, length and position of the venous cannula usually limit the ECMO blood flow rate. In our study, the venous cannula was placed as deep as the diaphragm, with its multiple side holes covering the full length of the caval veins and the right atrium. With this placement, the ECMO blood flow rate during ECMO-CPR could be kept as high as baseline CO pre-arrest without incidents of "suck down", and increased CVP could be avoided. The low MPAP during ECMO-CPR indicated a relatively low blood flow through the pulmonary circulation, and thus a limited amount of blood entering the LV. This venous unloading, combined with adequate myocardial perfusion, is known to be particularly important to the post-arrest myocardium \[[@CR31]\].

In peripheral veno-arterial ECMO, blood from the arterial cannula flows upwards in the descending aorta, increasing LV afterload. LV distension may then develop with compromised myocardial perfusion and hydrostatic pulmonary oedema. Although coronary perfusion was not measured, serious hypo-perfusion was most likely prevented by our protocol with the attention to adequate MAP and pulse pressure, the latter to assure LV emptying. The pressures were maintained above the lower limits by the customised dosage of positive inotropic medication. Dobutamine enhance LV function post-arrest \[[@CR32]\]. All pigs could be weaned from extracorporeal support in accordance with the study protocol---this success would not have been possible after ECMO-CPR with severely compromised myocardial perfusion.

LV function after ECMO-CPR {#Sec22}
--------------------------

Cardiac MRI is often considered as the reference standard for the assessments of LV volumes and function. In addition, we assessed post-arrest LV haemodynamics by a PA catheter and a LV pressure transducer. Cardiac MRI demonstrated a severe impairment of LV function after ECMO-CPR. The systolic dysfunction was evident both by the global volume and flow measurements and by the LV motion measurements, mid LV radial wall thickening, MAPSE, and global systolic circumferential strain. Interestingly, post-arrest dysfunction was characterised by almost similar reductions (approximately 50--70 %) of systolic LV motion in all three deformation directions, indicating a global LV impairment.

When compared to cardiac MRI the LVP and dP/dt measurements did not reflect the severity of systolic LV dysfunction. LVP was maintained because MAP was pharmacologically sustained as prescribed by the protocol. An increased inotropic state post-arrest-a result of the dobutamine infusion and an endogenous catecholamine response \[[@CR33], [@CR34]\] probably contributed to the observed increase in dP/dt~max~ and HR \[[@CR35], [@CR36]\]. In addition, an increased afterload (Ea) post-arrest and a shorter systolic duration and IVC may also have influenced the dP/dt variable \[[@CR37], [@CR38]\]. The CO~PA~ and SV~PA~ measurements, however, corresponded well with the MRI measurements, but PA assessments gave less information.

In addition to the success of ECMO-CPR, our study demonstrates that a detailed assessment of early post-arrest LV dysfunction is feasible by cardiac MRI. The model may be relevant for future research on ECMO-CPR strategies and cardiac outcome.

Diastolic LV dysfunction was not demonstrated by the LV function variables included in this study. Post-arrest ESV increased without changes in EDV or EDP, indicating reduced systolic emptying of a ventricle adequately filled in diastole. A preserved diastolic function was supported by an unaltered tau and dP/dt~min~ post-arrest, indicating normal LV relaxation. Taken together, this can imply that LV dysfunction after ECMO-CPR is a failure of myocardial contractile function, not predominantly related to LV relaxation ability. Increased HR and dP/dt~max~ with reduced SV, and preserved diastolic function with maintained dP/dt~min~, tau, and end-diastolic pressure-volume relationship have also been demonstrated after hypoxic cardiac arrest in pigs \[[@CR27]\]. Early post-arrest LV dysfunction in pre-arrest healthy hearts thus seems similar whether cardiac arrest is induced electrically or by hypoxia.

The reduced SV post-arrest was compensated for by an increased HR, maintaining CO and D~O2~. However, the substantial drop in mixed venous oxygen saturation indicates that D~O2~ was insufficient for the increased post-arrest metabolic needs. The increased V~O2~ may be due to recovery from oxygen debt and activation of other oxygen consuming processes such as systemic inflammation, induced by ischemia and reperfusion \[[@CR39]\].

Limitations {#Sec23}
-----------

Our experimental model was different from a clinical ECMO-CPR scenario. In our study, healthy pigs were included, and cardiac arrest was introduced electrically. The duration of no-flow-exceeding usual clinical limits was intended to achieve a combination of survival and a certainly measurable post-arrest cardiac dysfunction. Cardiovascular function was in focus, and no attention was paid to neurological or other organ outcome. Pre-arrest heparinisation is a common experimental approach that also differs from the later on (or omitted) clinical heparin administration. Sham-operated animals were decided not included as the experiments were completed without complications, haemodynamic stability was adequate (Fig. [1](#Fig1){ref-type="fig"}), and veno-arterial ECMO only does not seem to affect intrinsic function of the porcine heart \[[@CR40]\]. The reversibility of post-arrest myocardial LV dysfunction (stunning) was not addressed as it may take several days for the heart to fully recover. Some myocardial necrosis cannot be excluded, encouraging future investigations of myocardial damage related to ECMO-CPR in this model.

Conclusions {#Sec24}
===========

An ECMO-CPR strategy of 150-min veno-arterial ECMO aiming at high blood flow rate and pharmacologically sustained aortic blood pressure and pulse pressure allowed successful resuscitation of long-lasting cardiac arrest with adequate post-arrest haemodynamic stability in pigs. MRI imaging of the in vivo beating heart demonstrated a severe early post-arrest LV dysfunction. Systolic LV function variables were substantially reduced whereas diastolic function was preserved. Cardiac MRI will be a valuable tool for future research on post-arrest cardiac dysfunction including assessment of cardiac outcome after ECMO-CPR.
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HR

:   heart rate

CO~phase~ and SV~phase~

:   cardiac output and stroke volume by cardiac MRI phase-contrast technique

EDV

:   end-diastolic volume

ESV

:   end-systolic volume

Wall thickening ~septum~ and Wall thickening ~lat~

:   mid left ventricular radial wall thickening in septum and lateral wall

MAPSE~antsept~ and MAPSE~postlat~

:   mitral annular plane systolic excursion measured anteroseptally and posterolaterally

HR~PA,~ CO~PA~ and SV~PA~

:   pulmonary artery catheter assessments of heart rate, cardiac output and stroke volume

MAP

:   mean aortic pressure

CVP

:   central venous pressure

Wedge

:   pulmonary arterial wedge pressure

SVR

:   systemic vascular resistance

LVP~max~

:   systolic left ventricular pressure maximum

EDP

:   end diastolic pressure

dP/dt~max~ and dP/dt~min~

:   maximum and minimum LVP time derivates

tau

:   tsovolumetric relaxation constant

Ea

:   arterial elastance

DD

:   diastolic duration

SD

:   systolic duration

IVC

:   isovolumetric contraction time

S~V~O~2~

:   mixed venous oxygen saturation

D~O2~

:   oxygen delivery

V~O2~

:   oxygen consumption
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